What's Changed With Dendreon?

In this video, Motley Fool health-care bureau chief Brenton Flynn takes a closer look at Dendreon (Nasdaq: DNDN) , a company that has underperformed recently, to shareholders' chagrin. Brenton looked at the company's recent SEC filings and gives us a few interesting pieces of information about the company he gleaned from them. For one thing, the company had been sitting on some zero-cost antigen inventory, and benefiting from that wasn't being recognized as an expense. Second, the company made a sharp move by selling its royalty rights to Merck's (NYSE: MRK) hepatitis C drug Victrelis last year for $125 million.

Dendreon's run over the past four years witnessed sub-$5 share prices skyrocket to 10-bagger status before tumbling all the way back down below $5, as its revolutionary prostate cancer vaccine Provenge became a lightning rod of debate. But where does that leave investors -- other than a bit nauseated from the roller-coaster ride? Our own David Williamson answers this question, and many more, inside our brand new premium research report on Dendreon. Inside, he details every key issue facing the company and outlines just how Dendreon intends to regain its former glory. The report also comes with a full year of analyst updates, so claim your copy of this exclusive report today by clicking here now.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.